Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:1055  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
 


 
   Table of Contents     
ORIGINAL ARTICLE  
Year : 2019  |  Volume : 11  |  Issue : 1  |  Page : 36-42
Global contributors to antibiotic resistance


1 Department of Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA
2 Department of Medicine, Rutgers New Jersey Medical School, Newark, New Jersey, USA
3 Department of Pharmacy, University Hospital, Newark, New Jersey, USA

Click here for correspondence address and email

Date of Web Publication7-Feb-2019
 

   Abstract 


Introduction: Antibiotic-resistant infections have become increasingly prevalent nowadays. As a result, it is essential to examine the key socioeconomic and political factors which contribute to the rise in the prevalence of antibiotic resistance in developing and developed nations. This study aims to identify the various contributors to the development of antibiotic resistance in each type of nation. Methods: PUBMED was used to identify primary research, systematic reviews, and narrative reviews published before Jan 2017. Search terms included antibiotic resistance, antimicrobial resistance, superbugs, multidrug-resistant organisms, developing countries, developed countries. Publications from different countries were included to ensure generalizability. Publications were excluded if they didn't mention factors causing resistance, focused on the molecular basis of resistance, or if they were case reports. Publicly available reports from national and international health agencies were used. Results: In developing countries, key contributors identified included: (1) Lack of surveillance of resistance development, (2) poor quality of available antibiotics, (3) clinical misuse, and (4) ease of availability of antibiotics. In developed countries, poor hospital-level regulation and excessive antibiotic use in food-producing animals play a major role in leading to antibiotic resistance. Finally, research on novel antibiotics is slow ing down due to the lack of economic incentives for antibiotic research. Conclusion: Overall, multiple factors, which are distinct for developing and developed countries, contribute to the increase in the prevalence of antibiotic resistance globally. The results highlight the need to improve the regulatory framework for antibiotic use and research globally.

Keywords: Antibiotic resistance, developed countries, developing countries, socioeconomic driving forces

How to cite this article:
Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Global Infect Dis 2019;11:36-42

How to cite this URL:
Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Global Infect Dis [serial online] 2019 [cited 2022 Jan 24];11:36-42. Available from: https://www.jgid.org/text.asp?2019/11/1/36/251836





   Introduction Top


Infectious diseases have been a major cause of mortality historically. However, developments within medicine and public health during the 20th century helped to markedly reduce the burden associated with infectious diseases. In 1900, infectious diseases accounted for one-third of all deaths out of the top 10 leading causes of death.[1] On the contrary, in 2014, noncommunicable diseases such as cardiovascular illness and cancers accounted for the majority of deaths.[2] Key medical breakthroughs, such as the discovery of penicillin, as well as improved sanitation played crucial roles in reducing the mortality associated with infections.[1] Fleming's discovery of penicillin heralded in the “golden era” of antibiotic development, during which many new antibiotics were developed and introduced, causing many to believe that infectious diseases would soon be conquered.[3] However, infectious diseases are again on the rise, especially those which can no longer be treated using the previously discovered antibiotics. Infectious pathogens are able to evolve and therefore over time, many have developed resistance to the currently-prescribed and newly-developed antibiotics. In fact, antibiotic resistance has become a significant threat to the health of individuals at the global level. Methicillin-resistant Staphylococcus aureus (MRSA) kills nearly 50,000 individuals every year in the United States and Europe alone, with many more dying from it in other settings.[4] Antibiotic-resistant diseases such as tuberculosis (TB) have significant impacts on developing countries. In 2013, there were approximately 480,000 cases of multidrug-resistant TB.[4] Since both developed and developing countries are equally affected by antibiotic-resistant infections, it is important to analyze antibiotic resistance development globally. Although it is difficult to get accurate estimates of drug resistance, it is predicted that antimicrobial-resistant infections will lead to nearly 10 million deaths per year by 2050 and a total GDP loss of $100.2 trillion by 2050 if appropriate actions are not taken.[4] Since infectious pathogens are constantly evolving and developing antibiotic resistance, it is essential to examine the key socioeconomic and political factors which contribute to the rise in the prevalence of antibiotic resistance in developing and developed nations. The purpose of this study was to conduct a qualitative literature review of the various factors contributing to the rise in antibiotic resistance globally. This paper aims to highlight that there are distinct factors which play a role in increasing the prevalence of antibiotic resistance in developing and developed countries and argues that more measures need to be taken at international and national levels to improve the regulatory framework to slow the development of antibiotic resistance and augment research into novel therapies.


   Methods Top


PUBMED was used to identify primary research, systematic reviews, and narrative reviews published between 1963 and January 2017. Search terms included antibiotic resistance, antimicrobial resistance, superbugs, multidrug-resistant organisms, developing countries, developed countries. Publications from different countries were included to ensure generalizability. Publications were excluded if they did not mention factors causing resistance, focused on the molecular basis of resistance, or if they were case reports. Publications in languages other than English were also excluded. Publicly available reports from national and international health agencies were used.


   Results Top


Search results yielded 2281 publications for developing nations and 1227 publications for developed nations. Publications were screened based on their titles and abstracts. Case reports as well as publications which did not focus on socioeconomic and political contributors to antibiotic resistance were excluded. Finally, 18 publications from developing nations and 13 publications from developed nations were included in the review. In addition, six publicly available reports from the World Health Organization (WHO), Centers of Disease Control, and the Food and Drug Administration (FDA) were utilized [Figure 1].
Figure 1: Flowchart illustrating the study selection process

Click here to view


In developing nations, key contributors identified included: (1) Lack of surveillance of resistance development, (2) poor quality control of available antibiotics, (3) clinical misuse, and (4) ease of availability. In contrast, in developed countries, factors contributing to antibiotic resistance included: (1) poor hospital-level regulation and (2) overuse of antibiotics in food-producing animals. Finally, there is a significant lack of research on new antibiotics, which affects both developing and developed nations [Figure 2]. Each of these factors will be discussed in more detail in the subsequent sections.
Figure 2: Major socioeconomic and political factors contributing to antibiotic resistance in developing (green), developed (red) countries, and both developing and developed countries (gray)

Click here to view


Developing nations

Lack of surveillance of resistance development

While it is essential to maintain proper surveillance of antibiotic resistance development, in most developing countries, there is little to no such surveillance. In 2014, the WHO released the first report on antimicrobial resistance, in which the WHO collected national data on nine bacterial infections/antibiotic combinations of greatest concern for global health.[5] The data revealed that out of 194 countries, only 129 provided data, of which only 22 had data on all nine infection-antibiotic resistance combinations deemed to be emerging global threats.[5],[6] The 2014 WHO report was the first attempt to obtain a more comprehensive analysis of the extent of worldwide antimicrobial resistance. The report not only highlighted the high levels of antibiotic resistance globally but also the lack of coordination and significant gaps in surveillance, especially in many of the developing countries with high burden of antibiotic resistance from where no national data was obtained.[5] In order to narrow the gaps in surveillance, the WHO has since launched the Global AMR surveillance system (GLASS), in which more than one-fourth of the WHO member states have been enrolled until December 2017.[7] Currently, there are still many limitations, especially in the developing countries where resources and proper infrastructure are necessary to improve surveillance of antimicrobial resistance development.[7]

Poor quality of available antibiotics

Many developing countries do not have the necessary quality assurance mechanisms to ensure that antibiotics being supplied are high quality. A 2006 Nigerian study showed that nearly 25%–40% of ampicillin/cloxacillin antibiotic formulations were substandard.[8] It has also been shown that the use of expired pediatric antibiotics led to higher rates of resistance when compared to unexpired medicines.[9] Resistance rates are in fact increased by 2–6 fold when using expired medications compared to unexpired medications. Substandard and expired antibiotics are sold for a number of reasons.[9] The expiration date printed gives consumers information about the shelf life of a medicine given that it is stored in proper conditions of light, temperature, and moisture.[10] However, high temperatures, harsh sunlight, and humidity can all lead to antibiotic degradation.[10] If the actual medicine storage and transport conditions deviate from the recommended ones, then it is possible that a larger than expected percentage of medicines are degraded, catching both health-care workers and the patient unaware that the patient is receiving a subtherapeutic dose.[9] The tropical conditions in some of the developing nations in addition to a lack of attention on proper transport methods affect the quality of the antibiotics.[10] Many medications also get relabeled near the end of their shelf life and get donated rather than sold.[9],[10] Finally, counterfeit drugs, in which there is little to no active ingredient, are also sold and can lead to increases in development of drug resistance. All of these facts underscore the need to improve quality assurance and enforcement of the antibiotic good manufacturing practice globally.

Clinical misuse of antibiotics

Clinical misdiagnosis and antibiotic misuse also contribute to antibiotic resistance due to the excessive use of antibiotics when not clinically indicated. It has been shown that proper diagnostic methods are often not utilized when treating infections and therefore antibiotics are prescribed when not necessary.

A study in a Chinese University hospital highlighted that of 1025 cases where antibiotics are prescribed, only 39 had a microbiological examination done to identify the source of the infection.[11] The same study showed that nearly 77.8% of patients were prescribed 1 or more antibiotics.[11] Similarly, in Jakarta, Indonesia, 94% of children with diarrhea were prescribed antibiotics despite most physicians suspected it to be a viral infection.[12] There has been significant work done by the WHO to create international standards toward improving clinical diagnosis for TB. Despite these efforts, there has been little use and availability of these new diagnostic tools. Molecular tests such as the GeneXpert are recommended for TB diagnosis.[13] However, in India, this test is recommended only for HIV-associated TB and multidrug-resistant TB rather than for all TB cases primarily due to the cost of these tests.[13] Similarly, the use of these molecular tests is either not implemented or partially implemented in most developing nations.[13] While the use of drug sensitivity tests is currently recommended for any patient with a history of previous anti-TB treatment, positive smear test after 3 months of treatment, or treatment failure/relapse, only 39% of providers performed a drug sensitivity test for such cases according to a study in India.[14] Microbiological bacterial culture and drug sensitivity tests are rarely done in many developing countries. Other diagnostic tests used to confirm infection are uncommon and unreliable, and therefore, many clinicians only rely on clinical signs and symptoms rather than the recommended laboratory tests. Consequently, there is an increased use of broad-spectrum antibiotics, which in turn breeds resistance because it selects for resistant organisms within the normal intestinal flora which may be harmless at index antibiotic administration but can transfer resistance to future pathogenic infections.[15] As a result, the lack of proper diagnostic methods can lead to increases in drug resistance.

Studies have also shown that clinical misuse of antibiotics is more common among private practitioners than those in the public sector.[10],[16] A retrospective analysis of the antibiotic prescribing practices in Malaysia showed that while in public clinics the antibiotic prescribing rate was 6.8%, in private settings the antibiotic prescribing rate was 30.8%.[16] While the WHO has developed the directly observed treatment, short-course (DOTS) TB treatment guidelines according to the level of drug resistance, studies in India have found that most private treatments were irrational and not compliant with these recommendations.[14] A 2010 study from Mumbai, India, found that when 106 private practitioners were asked to write a prescription for a patient with pulmonary TB, 63 different drug regimens were prescribed and only 6 of those were appropriate.[17] Since some physicians depend on both patients' fees and the kickbacks they receive from the pharmaceutical industry, there is little incentive to join and adhere to the nationwide DOTS program.[17] The unregulated private sector leads to improper diagnostic and prescribing practices which in turn contributes to selection for resistant organisms and lead to increasing antibiotic resistance.

Ease of availability of antibiotics

In most developing countries, there is little regulation on the retail of pharmaceuticals. The ease of availability of antibiotics is probably one of the biggest contributors to antibiotic resistance. Antibiotics are available often without a physician's prescription, contributing to the overuse of antibiotics due to self-medications and prescriptions by unskilled health workers. In Minya, Egypt, a study of antibiotic use showed that 81% of pharmacists prescribe antibiotics for colds.[18] In many countries in Asia, Africa, and Latin America, antibiotics are readily available from local pharmacies, hospitals, drugstores, roadside stalls, and hawkers without a prescription.[10] In rural Bangladesh, a study of 2000 participants showed that 95% of the medications consumed came from local pharmacies, and only 8% of these were prescribed by physicians.[10] A similar study was done to identify drug dispensing patterns to standardized TB patients in India who visited 623 pharmacies in three major cities.[19] While in confirmed TB cases 61% of patients were ideally managed and referred to a health-care center without drug dispensing, in presumptive cases only 13% of the patients were managed in this way.[19] These number may be drastically different in rural settings where high illiteracy rates and unqualified pharmacists may compound the problem.[20] While steps are being taken to improve regulations in many countries including India, there are still many milestones to be achieved.[21]

In many developing countries and especially in rural areas, there is a lack of available skilled doctors and health workers who are certified to diagnose and treat ailments.[10] As a result, many unskilled health workers with minimal training as well as traditional healers treat ailments and prescribe antibiotics.[10] A study in rural India on childhood diarrhea and pneumonia showed that out of 340 health-care practitioners included in the study, 80 of them had no formal education.[22],[23] In addition, the study showed that unqualified practitioners were more likely to prescribe harmful treatments.[23] Unskilled health workers and healers often have little to no understanding of the consequences of unregulated antibiotic use.

Developed nations

The issue of antibiotic resistance is not limited to developing nations. Even industrialized countries face the global threat of drug-resistant infections. In many high- and middle-income countries, prophylactic antibiotics are used extensively for common procedures such as cesarean sections, joint replacements, and organ transplants. Antibiotics are also given prophylactically to patients undergoing chemotherapy, which lowers immunity.[4] Finally, intercontinental travel has become very common now and therefore increases the speed and extent of spread of drug-resistant pathogens, making antibiotic resistance an equally significant public health threat in developed countries.[4] Thus, it is important to analyze the socioeconomic driving forces behind antibiotic resistance development in high-income industrialized nations. Similar factors as those in the developing nations play a role in breeding drug resistance in the United States, including inappropriate prescribing practices by clinicians and poor patient compliance. Many uninsured individuals and those living below the poverty line get antibiotics from unreliable sources within the United States or from foreign countries. In 2003, out of 1153 shipments arriving in Miami, New York, and California, nearly 88% of these shipments contained unapproved medications from various countries.[24] Many individuals, of whom nearly 80% were uninsured, frequently visit Mexico to get access to antibiotics readily without needing a prescription.[24],[25] In addition to improper imports, self-medication is also a significant problem in industrialized countries. A prospective survey conducted in an emergency department of a hospital showed that nearly 17% of the patients took “left-over” medications when they experienced a cough or sore throat.[24],[26] Sharing of medications is also common in which patients use “left-over” antibiotics initially prescribed to other individuals.[24] However, while similar factors such as the ease of availability of antibiotics from unreliable sources are also present in industrialized countries, there are other distinct factors which play a much greater role in contributing to resistance development in these countries.

Poor hospital-based antibiotic use regulation

Hospital-acquired infections (nosocomial infections) remain one of the major sources of antibiotic-resistant infections in developed countries. Antibiotics are used extensively in hospitals to not just treat patients with bacterial infectious diseases but also prophylactically to reduce risk of infections during procedures and surgeries. The excessive use of antibiotics coupled with close patient–patient interactions and the need for increased hygiene and sanitation within hospitals play a significant role in development and transmission of drug-resistant bacterial infections.[27] Statistics show that rates of resistance in nosocomial infections have been rising and the primary driving factors include the unregulated overuse of antibiotics and cross-transmission between patients, which is often due to infrequent handwashing and hand gloving.[27] However, increasing regulations within hospitals have proven to be successful in reducing the burden of hospital-associated infections, especially for drug-resistant infections. Many hospitals have adopted policies requiring health-care workers to frequently wash hands in between different patients, installed alcohol-based hand rubs outside of patient rooms, and requiring universal gloving during all patient interactions.[27] While these interventions lower cross-transmission of already resistant organisms, they do not affect the rate of development of antibiotic resistance which occurs due to inappropriate antibiotic prescribing practices.

It has been shown that hospital-level monitoring and restrictions on antibiotic use have been the most useful to improve antibiotic prescribing practices.[28] Many hospitals have begun antimicrobial stewardship programs consisting of interdisciplinary teams to monitor antimicrobial use and identify ways to reduce development and transmission of drug resistance.[28] Some of the ways to lower resistance development include limiting prescribing options to one or two antibiotics per class, regularly providing feedback to doctors after their antibiotic prescriptions, as well as utilizing a decision-support algorithm to provide patient-specific laboratory results and local resistance patterns.[27],[28] Similarly, it has been found that rotating the drug being used within a specific class of antibiotics can also help reduce incidences of resistance development as it relieves selective pressure on the organisms by a single antimicrobial agent.[27],[28] A systematic review of the various studies done on the effectiveness of antimicrobial stewardship programs shows that such initiatives are associated with reductions in antimicrobial use, shorter duration of antibiotic therapy, less clinical misuse, and fewer adverse reactions.[29] In addition, it also shows that antimicrobial stewardship programs longer than 6 months are also associated with reduced development of drug resistance though that depends on the specific pathogen and antibiotic being used.[29]

Overall, the effects of antimicrobial stewardship programs also highlight the key role effective regulations and policy enforcement play in reducing the burden of antibiotic resistance. However, while many hospitals have adopted such a strategy, data from 2014 shows that only 39.2% of US hospitals have an antimicrobial stewardship program.[30] In fact, in several regions of the country, only 7%–28% of hospitals have similar programs to lower hospital-associated infections and antibiotic resistance.[30]

Excessive use of antibiotics in food-producing animals

Another area which has been debated as being one of the contributors to antibiotic-resistant infections includes the use of antibiotics in food-producing animals. In order to understand the role of antibiotic use in food-producing animals, it is first important to understand the extent of antibiotic use in animals as well as the complex interactions between different components which lead to antibiotic resistance in humans. Antibiotics are not only used to treat diseases in animals but also prophylactically to prevent infections and nontherapeutically to increase animal growth.[31] Many of these uses often overlap and are used simultaneously in livestock. A 2013 FDA report highlights the extent to which antimicrobials are used in food-producing animals.[32] Data reveal that the sales of antimicrobials increased by nearly 26% from 2009 to 2015. In addition, in 2016, 96% of antimicrobials for medical and nonmedical use were sold over-the-counter without needing a veterinary prescription; nearly 7–9 million medically important drugs and 4–6 million nonmedically important drugs were sold annually for use in food-producing animals since 2009, in which medically important drugs refer to the FDA's guidelines for industry use of medications important for human medical therapy.[32] These statistics illustrate the extent of antimicrobial use in animals without any veterinary regulation.

The complex web of interactions between humans and animals eventually lead to transmission of infectious agents and antibiotic resistance into human pathogens. Antibiotic use in food-producing animals can have both direct and indirect consequences for human health.[31] For instance, consumption of meat products contaminated with antibiotic-resistant pathogens can lead to outbreaks of resistant diseases.[31] It can also increase colonization of resistant bacteria and therefore induce resistance in the normal flora of the gastrointestinal tract.[31] Contamination of animal feces with drug-resistant species can also lead to eventual transmission to humans through soil and water.[31] Overall, this complex web of animal-human interactions leads to transmission of drug-resistant bacterial species into humans.

The significant use of antibiotics in food-producing animals as well as the transmission to humans of drug-resistant species is a cause for concern. A study done on the incidence and prevalence of antibiotic-resistant S. aureus on meat and chicken samples in Turkey shows that out of 80 S. aureus strains isolated and identified, 67.5% were found to be resistant to methicillin and 87.5% were resistant to bacitracin.[33] A similar study in the United States examining the colonization of MRSA in swine and swine workers on two large swine production farms illustrated that 45% of the workers were colonized with a MRSA strain which was similar to that found in the swine but different from strains normally found in humans.[34] In fact, many studies done globally have all confirmed that the association between antibiotic use in food-producing animals and the presence of antibiotic-resistant bacterial species from those animals on meat products and in human infections.[31] These facts highlight the key role of antibiotic use in food-producing animals as a major driving force behind the rise in the prevalence of antibiotic resistance.

Developing and developed nations

Lack of research on new antibiotics

Despite the evidence that antibiotic resistance is a key issue and an emerging global threat, research on new antibiotic medications to combat infectious diseases is slowing down.[35] While the period between the 1950s and 1970s led to discoveries of many new antibiotics from a variety of different classes, no new antibiotic class has been discovered since then.[35] Only 3% of the new medications approved by the FDA between January 1998 to December 2002 were new antibacterials.[3] While there were 19 antibacterial new drug application approvals between 1980 and 1984, there were only six such approvals from 2010 to 2014.[36] 15 of the 18 pharmaceutical companies have left the antibiotic field and the mergers between different companies have diminished the number and diversity of research teams.[36] While the discovery of antibiotics in the early 20th century heralded in the golden age of antibiotic research, currently there are little incentives to continue on the same path. The WHO published a report in September 2017 arguing that the antibiotics currently in clinical development are not sufficient to counter rising antimicrobial resistance, particularly the pathogens with greatest threat to human.[37]

The lack of economic incentives and regulatory hurdles are the biggest driving forces behind the lack of novel antibiotics currently. The net present value (NPV) is the measure used by pharmaceutical companies to determine ways to invest money into various projects.[38] The NPV of antibiotics is much lower than other therapeutic classes, especially for noncommunicable diseases, and therefore, antibiotic research is not an economically favorable investment for these companies.[38] The NPV of a medication to treat neuromuscular disease is about $1 billion compared to the NPV of an antibiotic which is only about $50 million according to the Office of Health Economics in London.[39] Antibiotics are used for a relatively short period of time whereas medications for chronic diseases are used for a longer period of time, giving the pharmaceutical companies more economic returns.[36],[38] In addition, many of the existing antibiotics are off-patent and therefore are produced by generic manufacturers.[38] Any new antibiotic would have to compete in the market with generic drugs, which often do work on patients and are less expensive.[38] In addition, new antibiotics are considered to be the last-line drugs, which physicians prescribe as a last resort when older antibiotics do not work, reducing sales for the pharmaceutical company investing in the drug development process.[36] In addition to the lack of economic incentives, there are also much greater risks in antibiotic drug discovery. Bacterial species are continuously evolving in response to the selection pressure placed upon them by the antibiotics, though the time to resistance development is variable.[36] As a result, it is possible that many new antibiotics lead to resistance prematurely, during the clinical trials itself.

Regulatory barriers have also led companies away from this area of research. Changing the FDA standards for clinical trials have made antibiotic discovery more challenging. For instance, it is considered unethical to run a placebo-controlled clinical trial and pharmaceutical companies are required to show that the new antibiotic is as efficacious as the older drugs.[36] This requires clinical trials with larger sample sizes and therefore higher costs.

Steps are being taken to encourage more research and development in the antibiotic arena. In 2013, the FDA revised its guidelines for clinical trial requirements for acute bacterial skin and skin structure infections, providing more clarity and guidance and helping companies lower costs for clinical trials.[36] The Infectious Disease Society of America has also proposed the limited-population antibiotic drug mechanism which would allow antibiotic approval with smaller clinical trials, lowering costs and time commitments, and address a critical need.[39] With this mechanism, the new antibiotic would be approved for a limited population of high-risk patients.


   Conclusion Top


Overall, looking at the current state of the global burden of infectious diseases and antibiotic resistance, it becomes evident that there are multiple driving forces behind the current situation. The results also highlight that there are distinct socioeconomic and political factors leading to antibiotic resistance in developing and developed countries. The primary contributors to resistance development in developing countries include poor surveillance of drug-resistant infections, poor quality of available antibiotics, clinical misuse, and the ease of availability of antibiotics. While similar factors such as self-medication and the lack of regulation on medication imports play a role in developed countries, this is to a much lower extent than in developing nations. In contrast, key contributing factors in developed countries include poor hospital-based antibiotic use regulation and the excessive use of antibiotics in food-producing animals. Finally, there is a decrease in research on novel drugs to continue fighting against infections. In order to combat antibiotic resistance, it is essential to have two key elements: (1) improving the regulatory framework to control antibiotic use globally and (2) promote research on novel antibiotics. It is important to have clear guidelines which are set in place by an International Health Agency, such as the WHO, in order to maintain consistency across nations. However, since each country has a different health care and regulatory system, the specific policies to manage antibiotic use would need to be left to the individual nations. In addition, different aspects of the regulatory system would need to be further improved based on the specific challenges needed to overcome in that country. Whereas in developing countries, the manufacturing process, quality, availability, and use of antibiotics need to be further controlled, in developed nations, hospital-based interventions and antibiotic use in food-producing animals need to be regulated. In addition, further research needs to be promoted in order to develop new antibacterials which can be used in the future. Finally, there also needs to be incentives for nations to adopt a stronger regulatory framework to implement these guidelines. In addition, international agencies should also provide aid for resource-poor countries to develop the necessary infrastructure and to overlook the regulatory processes within each nation. Steps in the right direction are being taken by the WHO currently as they have created a Global Antimicrobial Resistance Surveillance System (GLASS) which collaborates with regional and national antimicrobial resistance surveillance systems to provide comprehensive and timely data. Similar efforts to regulate each of the different contributing factors would help lower the rate of resistance development globally.


   Summary Top


This study aims to provide a broad overview of the various different factors which contribute to antibiotic resistance globally. In this review, studies from diverse geographical regions have been analyzed and therefore it helps ensure that the results presented are generalizable to various different developing and developed countries. In addition, reports from national and international agencies have also been utilized to support the findings. Due to the diverse types of research studies utilized in this paper for each of the contributing factors, it is not possible to combine the results into a single statistic. Further research such as a meta-analysis focusing on a single contributing factor may help to combine the results of multiple studies into a single statistic. However, this paper serves as a building block for these further studies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Achievements in Public Health, 1900-1999: Control of Infectious Diseases. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm#fig2. [Last accessed on 2017 Feb 22].  Back to cited text no. 1
    
2.
The Top 10 Leading Causes of Death in the United States – Medical News Today Available from: http://www.medicalnewstoday.com/articles/282929.php. [Last accessed on 2017 Mar 15].  Back to cited text no. 2
    
3.
Conly J, Johnston B. Where are all the new antibiotics? The new antibiotic paradox. Can J Infect Dis Med Microbiol 2005;16:159-60.  Back to cited text no. 3
    
4.
O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. London, UK: World Health Organization; 2014.  Back to cited text no. 4
    
5.
World Health Organization | Antimicrobial Resistance: Global Report on Surveillance; 2014. Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/. [Last accessed on 2017 Mar 05].  Back to cited text no. 5
    
6.
Reardon S. Antibiotic resistance sweeping developing world. Nature News 2014;509:141.  Back to cited text no. 6
    
7.
World Health Organization | Global Antimicrobial Resistance Surveillance System (GLASS) Report Early Implementation. World Health Organization; 2018. Available from: http://www.apps.who.int/iris/bitstream/handle/10665/259744/9789241513449-eng.pdf; jsessionid=A32FA92510A66E6B2B337907B4F30C88?sequence=1. [Last accessed on 2018 Jun 19].  Back to cited text no. 7
    
8.
Obodozie OO, Mustapha KB, Ebeshi BU, Inyang US. A comparative study on the prevalence of substandard ampicillin/cloxacillin preparations in the Nigerian market: Mid 1990's and present. J Phytomed Ther 2006;11:1-8. [Doi: 10.4314/jopat.v11i1.48619].  Back to cited text no. 8
    
9.
Ogunshe A, Adinmonyema P. Evaluation of bacteriostatic potency of expired oral paediatric antibiotics and implications on infant health. Pan Afrs Med J 2014;19:378. doi: 10.11604/pamj. 2014.19.378.2156.  Back to cited text no. 9
    
10.
Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis 1999;5:18-27.  Back to cited text no. 10
    
11.
Hu S, Liu X, Peng Y. Assessment of antibiotic prescription in hospitalised patients at a Chinese University hospital. J Infect 2003;46:161-3.  Back to cited text no. 11
    
12.
Gani L, Arif H, Widjaja SK, Adi R, Prasadja H, Tampubolon LH, et al. Physicians' prescribing practice for treatment of acute Diarrhoea in young children in Jakarta. J Diarrhoeal Dis Res 1991;9:194-9.  Back to cited text no. 12
    
13.
StopTB Partnership. Out of Step 2015 TB Policies in 24 Countries A Survey of Diagnostic and Treatment Practices; 2015. Available from: http://www.stoptb.org/assets/documents/news/report_out_of_step_2015_11_pdf_with_interactive_links.pdf. [Last accessed on 2018 Jun 25].  Back to cited text no. 13
    
14.
Achanta S, Jaju J, Kumar AM, Nagaraja SB, Shamrao SR, Bandi SK, et al. Tuberculosis management practices by private practitioners in Andhra Pradesh, India. PLoS One 2013;8:e71119.  Back to cited text no. 14
    
15.
Dancer SJ. The dangers of broad spectrum antibiotics. BMJ 2003;326:1111.  Back to cited text no. 15
    
16.
Ab Rahman N, Teng CL, Sivasampu S. Antibiotic prescribing in public and private practice: A cross-sectional study in primary care clinics in Malaysia. BMC Infect Dis 2016;16:208.  Back to cited text no. 16
    
17.
Ecks S, Harper, Ian ND. There is no regulation, actually: The private market for anti-TB drugs in India. In: When People Come First: Anthropology & Social Innovation in Global Health. Durham, NC: Duke University Press; 2013.  Back to cited text no. 17
    
18.
Dooling KL, Kandeel A, Hicks LA, El-Shoubary W, Fawzi K, Kandeel Y, et al. Understanding antibiotic use in Minya district, Egypt: Physician and pharmacist prescribing and the factors influencing their practices. Antibiotics (Basel) 2014;3:233-43.  Back to cited text no. 18
    
19.
Satyanarayana S, Kwan A, Daniels B, Subbaraman R, McDowell A, Bergkvist S, et al. Use of standardised patients to assess antibiotic dispensing for tuberculosis by pharmacies in urban India: A cross-sectional study. Lancet Infect Dis 2016;16:1261-8.  Back to cited text no. 19
    
20.
Kashyap RS, Husain AA. Over-the-counter drug distribution and tuberculosis control in India. Lancet Infect Dis 2016;16:1208-9.  Back to cited text no. 20
    
21.
Team CD. Chennai Declaration: 5-year plan to tackle the challenge of anti-microbial resistance. Indian J Med Microbiol 2014;32:221.  Back to cited text no. 21
[PUBMED]  [Full text]  
22.
Cousins S. Healing India's Traditional Healers [WWW Document]. The Development Set; 2016. Available from: https://www.thedevelopmentset.com/healing-india-s-traditional-healers-31f55fc9749b. [Last accessed on 2017 Mar 11].  Back to cited text no. 22
    
23.
Mohanan M, Vera-Hernández M, Das V, Giardili S, Goldhaber-Fiebert JD, Rabin TL, et al. The know-do gap in quality of health care for childhood diarrhea and pneumonia in rural India. JAMA Pediatr 2015;169:349-57.  Back to cited text no. 23
    
24.
Planta MB. The role of poverty in antimicrobial resistance. J Am Board Fam Med 2007;20:533-9.  Back to cited text no. 24
    
25.
Macias EP, Morales LS. Crossing the border for health care. J Health Care Poor Underserved 2001;12:77-87.  Back to cited text no. 25
    
26.
Richman PB, Garra G, Eskin B, Nashed AH, Cody R. Oral antibiotic use without consulting a physician: A survey of ED patients. Am J Emerg Med 2001;19:57-60.  Back to cited text no. 26
    
27.
Weinstein RA. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. Emerg Infect Dis 2001;7:188-92.  Back to cited text no. 27
    
28.
MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005;18:638-56.  Back to cited text no. 28
    
29.
Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N, et al. Impact of antimicrobial stewardship in critical care: A systematic review. J Antimicrob Chemother 2011;66:1223-30.  Back to cited text no. 29
    
30.
Centers for Disease Control and Prevention. Percent of Hospitals with Antibiotic Stewardship Programs by State, 2014. Centers for Disease Control and Prevention; 2014.  Back to cited text no. 30
    
31.
Landers TF, Cohen B, Wittum TE, Larson EL. A review of antibiotic use in food animals: Perspective, policy, and potential. Public Health Rep 2012;127:4-22.  Back to cited text no. 31
    
32.
SUMMARY REPORT on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. Food-Producing Animals; 2016.  Back to cited text no. 32
    
33.
Gundogan N, Citak S, Yucel N, Devren A. A note on the incidence and antibiotic resistance of Staphylococcus aureus isolated from meat and chicken samples. Meat Sci 2005;69:807-10.  Back to cited text no. 33
    
34.
Smith TC, Male MJ, Harper AL, Kroeger JS, Tinkler GP, Moritz ED, et al. Methicillin-resistant Staphylococcus aureus (MRSA) strain ST398 is present in Midwestern U.S. Swine and swine workers. PLoS One 2009;4:e4258.  Back to cited text no. 34
    
35.
Aminov RI. A brief history of the antibiotic era: Lessons learned and challenges for the future. Front Microbiol 2010;1:134.  Back to cited text no. 35
    
36.
Ventola CL. The antibiotic resistance crisis: Part 1: Causes and threats.PT 2015;40:277-83.  Back to cited text no. 36
    
37.
World Health Organization | ANTIBACTERIAL AGENTS IN CLINICAL DEVELOPMENT An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis. World Health Organization; 2017. Available from: http://www.apps.who.int/iris/bitstream/handle/10665/258965/WHO-EMP-IAU-2017.11-eng.pdf; jsessionid=F9C30889A3920B7D0154788F545E7E88?sequence=1. [Last accessed on 2018 Jul 09].  Back to cited text no. 37
    
38.
Mossialos E, Morel C, Edwards S, Berenson J, Gemmill-Toyama M, Brogan D. Policies and Incentives for Promoting Innovation in Antibiotic Research. Copenhagen, Denmark: European Observatory on Health Systems and Policies; 2010.  Back to cited text no. 38
    
39.
Bartlett JG, Gilbert DN, Spellberg B. Seven ways to preserve the miracle of antibiotics. Clin Infect Dis 2013;56:1445-50.  Back to cited text no. 39
    

Top
Correspondence Address:
Dr. Ziad Sifri
Rutgers New Jersey Medical School, 150 Bergen Street M228, Newark, New Jersey 07101
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jgid.jgid_110_18

Rights and Permissions


    Figures

  [Figure 1], [Figure 2]

This article has been cited by
1 Conjugated Polymers for Combatting Antimicrobial Resistance
Zijuan Wang, Hao Geng, Chenyao Nie, Chengfen Xing
Chinese Journal of Chemistry. 2022;
[Pubmed] | [DOI]
2 Controlled and localized antibiotics delivery using magnetic-responsive beads for synergistic treatment of orthopedic infection
Ali Shademani, John K. Jackson, Charles J. Thompson, Mu Chiao
Journal of Biomedical Materials Research Part A. 2022;
[Pubmed] | [DOI]
3 Design principles for bacteria-responsive antimicrobial nanomaterials
J.Y. Quek, E. Uroro, N. Goswami, K. Vasilev
Materials Today Chemistry. 2022; 23: 100606
[Pubmed] | [DOI]
4 Antibiotic use and resistance in a tertiary care hospital: knowledge and attitude among patients of orthopaedic and surgical wards in Malaysia
Zulsairi Mohd Pauzi, Bassam Abdul Rasool Hassan, Chin Fen Neo, Ali Haider Mohammed, Ali Blebil, Juman Dujaili
Journal of Pharmaceutical Health Services Research. 2022;
[Pubmed] | [DOI]
5 Prevalence, aetiology, antimicrobial susceptibility testing, and predictors of urinary tract infection among neonates with clinical sepsis: a cross-sectional study
Yasintha S. Lugira, Fransisca D. Kimaro, Mkhoi L. Mkhoi, Samuel G. Mafwenga, Angelina A. Joho, James J. Yahaya
Egyptian Pediatric Association Gazette. 2022; 70(1)
[Pubmed] | [DOI]
6 Pathogen Control in the Built Environment: A Probiotic-Based System as a Remedy for the Spread of Antibiotic Resistance
Maria D’Accolti, Irene Soffritti, Francesca Bini, Eleonora Mazziga, Sante Mazzacane, Elisabetta Caselli
Microorganisms. 2022; 10(2): 225
[Pubmed] | [DOI]
7 Audits of Antimicrobial Usage in a Tertiary Care Center in Hyderabad
Lakshmi Jyothi, Ariyanachi K, Saranya M, Chennakesavulu Dara, Varatharajan Sakthivadivel, Triven Sagar Sandepogu , Archana Gaur
Cureus. 2022;
[Pubmed] | [DOI]
8 Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole Schiff bases and molecular docking with ct-DNA and SARS-CoV-2 M pro
Sugandha Singhal, Pankaj Khanna, Leena Khanna
Luminescence. 2021; 36(6): 1531
[Pubmed] | [DOI]
9 Prevalence of Bacteria and Antimicrobial Resistance Genes in Hospital Water and Surfaces
Maira Aleem, Abdul R Azeem, Sidra Rahmatullah, Sufyan Vohra, Shumyila Nasir, Saadia Andleeb
Cureus. 2021;
[Pubmed] | [DOI]
10 Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: A Review
Eduardo C. Reynoso, Serena Laschi, Ilaria Palchetti, Eduardo Torres
Chemosensors. 2021; 9(8): 232
[Pubmed] | [DOI]
11 Are Semi-Quantitative Clinical Cultures Inadequate? Comparison to Quantitative Analysis of 1053 Bacterial Isolates from 350 Wounds
Thomas E. Serena, Philip G. Bowler, Gregory S. Schultz, Anna D’souza, Monique Y. Rennie
Diagnostics. 2021; 11(7): 1239
[Pubmed] | [DOI]
12 Host-Pathogen Adhesion as the Basis of Innovative Diagnostics for Emerging Pathogens
Alex van Belkum, Carina Almeida, Benjamin Bardiaux, Sarah V. Barrass, Sarah J. Butcher, Tugçe Çaykara, Sounak Chowdhury, Rucha Datar, Ian Eastwood, Adrian Goldman, Manisha Goyal, Lotta Happonen, Nadia Izadi-Pruneyre, Theis Jacobsen, Pirjo H. Johnson, Volkhard A. J. Kempf, Andreas Kiessling, Juan Leva Bueno, Anchal Malik, Johan Malmström, Ina Meuskens, Paul A. Milner, Michael Nilges, Nicole Pamme, Sally A. Peyman, Ligia R. Rodrigues, Pablo Rodriguez-Mateos, Maria G. Sande, Carla Joana Silva, Aleksandra Cecylia Stasiak, Thilo Stehle, Arno Thibau, Diana J. Vaca, Dirk Linke
Diagnostics. 2021; 11(7): 1259
[Pubmed] | [DOI]
13 Salmonella in Chicken Meat: Consumption, Outbreaks, Characteristics, Current Control Methods and the Potential of Bacteriophage Use
Kirsten Wessels, Diane Rip, Pieter Gouws
Foods. 2021; 10(8): 1742
[Pubmed] | [DOI]
14 Knowledge, Attitude, and Practice on Antibiotics and Its Resistance: A Two-Phase Mixed-Methods Online Study among Pakistani Community Pharmacists to Promote Rational Antibiotic Use
Faiz Ullah Khan, Farman Ullah Khan, Khezar Hayat, Tawseef Ahmad, Amjad Khan, Jie Chang, Usman Rashid Malik, Zakir Khan, Krizzia Lambojon, Yu Fang
International Journal of Environmental Research and Public Health. 2021; 18(3): 1320
[Pubmed] | [DOI]
15 Towards A Novel Multi-Epitopes Chimeric Vaccine for Simulating Strong Immune Responses and Protection against Morganella morganii
Asad Ullah, Sajjad Ahmad, Saba Ismail, Zobia Afsheen, Muhammad Khurram, Muhammad Tahir ul Qamar, Naif AlSuhaymi, Mahdi H. Alsugoor, Khaled S. Allemailem
International Journal of Environmental Research and Public Health. 2021; 18(20): 10961
[Pubmed] | [DOI]
16 Bioprospecting of Soil-Derived Actinobacteria Along the Alar-Hotan Desert Highway in the Taklamakan Desert
Shaowei Liu, Ting Wang, Qinpei Lu, Feina Li, Gang Wu, Zhongke Jiang, Xugela Habden, Lin Liu, Xiaolin Zhang, Dmitry A. Lukianov, Ilya A. Osterman, Petr V. Sergiev, Olga A. Dontsova, Chenghang Sun
Frontiers in Microbiology. 2021; 12
[Pubmed] | [DOI]
17 Cheminformatic Characterization of Natural Antimicrobial Products for the Development of New Lead Compounds
Samson Olaitan Oselusi, Alan Christoffels, Samuel Ayodele Egieyeh
Molecules. 2021; 26(13): 3970
[Pubmed] | [DOI]
18 Molecular diagnostics of Salmonella and Campylobacter in human/animal fecal samples remain feasible after long-term sample storage without specific requirements
CB Harder, S Persson, J Christensen, A Ljubic, EM Nielsen, J Hoorfar
AIMS Microbiology. 2021; 7(4): 399
[Pubmed] | [DOI]
19 Investigating the Antimicrobial Effects of Glycyrrhiza glabra and Salvia officinalis Ethanolic Extract Against Helicobacter pylori
Moharam Valizadeh, Fazal ur Rehman, Mohammad Amir Hassanzadeh, Maryam Beigomi, Bahman Fazeli-Nasab
International Journal of Infection. 2021; In Press(In Press)
[Pubmed] | [DOI]
20 Evaluation of P450 monooxygenase activity in lyophilized recombinant E. coli cells compared to resting cells
Thomas Hilberath, Alessandra Raffaele, Leonie M. Windeln, Vlada B. Urlacher
AMB Express. 2021; 11(1)
[Pubmed] | [DOI]
21 Non-prescription dispensing of antibiotic agents among community drug retail outlets in Sub-Saharan African countries: a systematic review and meta-analysis
Sewunet Admasu Belachew, Lisa Hall, Linda A. Selvey
Antimicrobial Resistance & Infection Control. 2021; 10(1)
[Pubmed] | [DOI]
22 Antibiotic resistance: still a cause of concern?
Malcolm R. DeBaun, Cara Lai, Mark Sanchez, Michael J. Chen, L. Henry Goodnough, Amy Chang, Julius A. Bishop, Michael J. Gardner
OTA International: The Open Access Journal of Orthopaedic Trauma. 2021; 4(3S): e104
[Pubmed] | [DOI]
23 Metagenome-Wide Analysis of Rural and Urban Surface Waters and Sediments in Bangladesh Identifies Human Waste as a Driver of Antibiotic Resistance
Ross Stuart McInnes, Md Hassan uz-Zaman, Imam Taskin Alam, Siu Fung Stanley Ho, Robert A. Moran, John D. Clemens, Md Sirajul Islam, Willem van Schaik, Zackery Bulman
mSystems. 2021; 6(4)
[Pubmed] | [DOI]
24 Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework
Alyssa M Pandolfo, Robert Horne, Yogini Jani, Tom W Reader, Natalie Bidad, David Brealey, Virve I Enne, David M Livermore, Vanya Gant, Stephen J Brett
BMJ Quality & Safety. 2021; : bmjqs-2020
[Pubmed] | [DOI]
25 Review on the Antibacterial Mechanism of Plant-Derived Compounds against Multidrug-Resistant Bacteria (MDR)
Najwan Jubair, Mogana Rajagopal, Sasikala Chinnappan, Norhayati Binti Abdullah, Ayesha Fatima, Armando Zarrelli
Evidence-Based Complementary and Alternative Medicine. 2021; 2021: 1
[Pubmed] | [DOI]
26 An Efflux Pumps Inhibitor Significantly Improved the Antibacterial Activity of Botanicals from Plectranthus glandulosus towards MDR Phenotypes
Gravalain Nanmeni, Alex T. Tedonkeu, Aimé G. Fankam, Armelle T. Mbaveng, Brice E. N. Wamba, Paul Nayim, Gabin T. M. Bitchagno, Raïssa T. Nzogong, Maurice D. Awouafack, Mathieu Tene, Veronique P. Beng, Victor Kuete, Jesus L. Romalde
The Scientific World Journal. 2021; 2021: 1
[Pubmed] | [DOI]
27 Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial
Marouf Alhalabi, Mohammed Waleed Alassi, Kamal Alaa Eddin, Khaled Cheha
BMC Infectious Diseases. 2021; 21(1)
[Pubmed] | [DOI]
28 Neonatal sepsis in Sana’a city, Yemen: a predominance of Burkholderia cepacia
Adeeb Salah, Ibrahim Al-Subol, Ahmed Hudna, Ali Alhaj, Abdulhabib R. Alqubaty, Waleed Farie, Dalal Sulieman, Ola Alnadhari, Talal Alwajeeh, Fawaz Alobathani, Abdullah Almikhlafy, Mohmmed A. K. Mahdy
BMC Infectious Diseases. 2021; 21(1)
[Pubmed] | [DOI]
29 Bibliometric analysis of peer-reviewed literature on antimicrobial stewardship from 1990 to 2019
Waleed M. Sweileh
Globalization and Health. 2021; 17(1)
[Pubmed] | [DOI]
30 Global research publications on irrational use of antimicrobials: call for more research to contain antimicrobial resistance
Waleed M. Sweileh
Globalization and Health. 2021; 17(1)
[Pubmed] | [DOI]
31 Antibacterial effects of peptides synthesized based on the sequence of ribosome protein S1
S.R. Kurpe, S.Yu. Grishin, A.V. Glyakina, M.V. Slizen, A.V. Panfilov, A.P. Kochetov, A.K. Surin, M.I. Kobyakova, R.S. Fadeev, O.V. Galzitskaya
Biomeditsinskaya Khimiya. 2021; 67(3): 231
[Pubmed] | [DOI]
32 Evaluation of Adult Outpatient Antibiotics Use at Jimma Medical Center (with Defined Daily Doses for Usage Metrics)
Tsegaye Melaku, Mulatu Gashaw, Legese Chelkeba, Melkamu Berhane, Sisay Bekele, Gemechu Lemi, Tekle Wakjira, Getnet Tesfaw, Zeleke Mekonnen, Solomon Ali, Arne Kroidl, Andreas Wieser, Guenter Froeschl, Esayas Kebede Gudina
Infection and Drug Resistance. 2021; Volume 14: 1649
[Pubmed] | [DOI]
33 Association between Awareness on Antibiotic Resistance and Antibiotic Misuse Among Saudi University Students
Ahmed Yousef Bu-Khamsin, Eduardo Fabella, Ali Habib Al Abdullah, Murtadha Radhi Albather, Yasser Taher Al-Hassan, Hassan Abdulfatah Alramadan, Abdullah Ahmed Al Moweshy, Ali Jameel Al Abdullah, Hassan Ibrahim Al Hassan
The Open Public Health Journal. 2021; 14(1): 545
[Pubmed] | [DOI]
34 Impact of Legislation on Antibiotic Use and Awareness of Beekeepers
Sofia Croppi, Lina Yu, Chris S. Robinette, Edgar E. Hassler, Adam J. Newmark, Andrew Scott, Joseph Cazier, Junxia Song, Giovanni Formato
Journal of Apicultural Science. 2021; 65(2): 265
[Pubmed] | [DOI]
35 Behaviors of Homologous Antibiotic Resistance Genes in a Cephalosporin WWTP, Subsequent WWTP and the Receiving River
Lei Chen, Mengyu Zhang, Daliang Ning, Joy D Van Nostrand, Yunfeng Yang, Jizhong Zhou, Jiane Zuo
Frontiers in Environmental Science. 2021; 9
[Pubmed] | [DOI]
36 Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach
Juliana Ochoa-Grullón, Celina Benavente Cuesta, Ataúlfo González Fernández, Gustavo Cordero Torres, Cristina Pérez López, Ascensión Peña Cortijo, Laura Conejero Hall, Marta Mateo Morales, Antonia Rodríguez de la Peña, Carmen M. Díez-Rivero, Edgard Rodríguez de Frías, Kissy Guevara-Hoyer, Miguel Fernández-Arquero, Silvia Sánchez-Ramón
Frontiers in Immunology. 2021; 11
[Pubmed] | [DOI]
37 Guidance for Demonstrating the Societal Value of new Antibiotics
Steven Simoens, Isabel Spriet
Frontiers in Pharmacology. 2021; 11
[Pubmed] | [DOI]
38 Exploring Undergraduate Pharmacy Students Perspectives Towards Antibiotics Use, Antibiotic Resistance, and Antibiotic Stewardship Programs Along With the Pharmacy Teachers’ Perspectives: A Mixed-Methods Study From Pakistan
Faiz Ullah Khan, Amjad Khan, Shahid Shah, Khezar Hayat, Abubakar Usman, Farman Ullah Khan, Zakir Khan, Yusuf Karatas, Tawseef Ahmad, Jie Chang, Usman Rashid Malik, Asad Khan, Sundus Shukar, Muhtar Kadirhaz, Yu Fang
Frontiers in Pharmacology. 2021; 12
[Pubmed] | [DOI]
39 Insects, Rodents, and Pets as Reservoirs, Vectors, and Sentinels of Antimicrobial Resistance
Willis Gwenzi, Nhamo Chaukura, Norah Muisa-Zikali, Charles Teta, Tendai Musvuugwa, Piotr Rzymski, Akebe Luther King Abia
Antibiotics. 2021; 10(1): 68
[Pubmed] | [DOI]
40 Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations
Paula Rojas-Garcia, Simon van der Pol, Antoinette D. I. van Asselt, Maarten J. Postma, Roberto Rodríguez-Ibeas, Carmelo A. Juárez-Castelló, Marino González, Fernando Antoñanzas
Antibiotics. 2021; 11(1): 27
[Pubmed] | [DOI]
41 Microplastics are a hotspot for antibiotic resistance genes: Progress and perspective
Yi Liu, Wenzhi Liu, Xiaomei Yang, Jie Wang, Hui Lin, Yuyi Yang
Science of The Total Environment. 2021; 773: 145643
[Pubmed] | [DOI]
42 Critical discovery and synthesis of novel antibacterial and resistance-modifying agents inspired by plant phytochemical defense mechanisms
Sameh S.M. Soliman, Balsam Qubais Saeed, Samia A. Elseginy, Farah Al-Marzooq, Islam M. Ahmady, Ali A. El-Keblawy, Rania Hamdy
Chemico-Biological Interactions. 2021; 333: 109318
[Pubmed] | [DOI]
43 Biocide-tolerance and antibiotic-resistance in community environments and risk of direct transfers to humans: Unintended consequences of community-wide surface disinfecting during COVID-19?
Bo Chen, Jie Han, Han Dai, Puqi Jia
Environmental Pollution. 2021; 283: 117074
[Pubmed] | [DOI]
44 The Total Chemical Synthesis and Biological Evaluation of the Cationic Antimicrobial Peptides, Laterocidine and Brevicidine
Yann Hermant, Dennise Palpal-latoc, Nadiia Kovalenko, Alan J. Cameron, Margaret A. Brimble, Paul W. R. Harris
Journal of Natural Products. 2021; 84(8): 2165
[Pubmed] | [DOI]
45 High prevalence of antibiotic resistance in commensal Escherichia coli from healthy human sources in community settings
Emmanuel Nji, Joseph Kazibwe, Thomas Hambridge, Carolyn Alia Joko, Amma Aboagyewa Larbi, Lois Afua Okyerewaa Damptey, Nana Adoma Nkansa-Gyamfi, Cecilia Stålsby Lundborg, La Thi Quynh Lien
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
46 Approaches for the inhibition and elimination of microbial biofilms using macromolecular agents
Lewis D. Blackman, Yue Qu, Peter Cass, Katherine E. S. Locock
Chemical Society Reviews. 2021; 50(3): 1587
[Pubmed] | [DOI]
47 Compliance with South Africa’s Antimicrobial Resistance National Strategy Framework: are we there yet?
Deirdré Engler, Johanna C. Meyer, Natalie Schellack, Amanj Kurdi, Brian Godman
Journal of Chemotherapy. 2021; 33(1): 21
[Pubmed] | [DOI]
48 Effects of different plant extracts at various dietary levels on growth performance, carcass traits, blood serum parameters, immune response and ileal microflora of Ross broiler chickens
Samantha Sigolo, Chrysostomos Milis, Mahmoud Dousti, Ebrahim Jahandideh, Ali Jalali, Noorouddin Mirzaei, Behrouz Rasouli, Alireza Seidavi, Antonio Gallo, Giulia Ferronato, Aldo Prandini
Italian Journal of Animal Science. 2021; 20(1): 359
[Pubmed] | [DOI]
49 Strategies to Combat Antimicrobial Resistance from Farm to Table
Gabriella Freeland, Navam Hettiarachchy, Griffiths G. Atungulu, Jason Apple, Soma Mukherjee
Food Reviews International. 2021; : 1
[Pubmed] | [DOI]
50 Antimicrobial Resistance: Physicians' and Pharmacists' Perspective
Doris Rusic, Josko Bozic, Josipa Bukic, Marino Vilovic, Marion Tomicic, Ana Seselja Perisin, Dario Leskur, Darko Modun, Tin Cohadzic, Sinisa Tomic
Microbial Drug Resistance. 2021; 27(5): 670
[Pubmed] | [DOI]
51 An Alternative to Antibiotics: Selected Methods to Combat Zoonotic Foodborne Bacterial Infections
Ewelina Lojewska, Tomasz Sakowicz
Current Microbiology. 2021; 78(12): 4037
[Pubmed] | [DOI]
52 Antimicrobial peptidomes of Bothrops atrox and Bothrops jararacussu snake venoms
Cleópatra Alves da Silva Caldeira, Rafaela Diniz-Sousa, Daniel Carvalho Pimenta, Ana Paula Azevedo dos Santos, Carolina Bioni Garcia Teles, Najla Benevides Matos, Saulo Luís da Silva, Rodrigo Guerino Stabeli, Silvia Andrea Camperi, Andreimar Martins Soares, Leonardo de Azevedo Calderon
Amino Acids. 2021; 53(10): 1635
[Pubmed] | [DOI]
53 An explorative study on diarylquinoline-based inhibitor targeting Enterococcus faecium MurF
Mohammed Afzal Azam, Vyshaag Chembakam veetil Manoj
Structural Chemistry. 2021; 32(1): 115
[Pubmed] | [DOI]
54 4-methoxybenzalacetone, the cinnamic acid analog as a potential quorum sensing inhibitor against Chromobacterium violaceum and Pseudomonas aeruginosa
Pornpimon Jantaruk, Wachirachai Pabuprapap, Archawin Nakaew, Duangkamol Kunthalert, Apichart Suksamrarn
World Journal of Microbiology and Biotechnology. 2021; 37(9)
[Pubmed] | [DOI]
55 Does Early Debridement, Antibiotic Therapy and Implant Retention (DAIR) have a Role in Managing Periprosthetic Joint Infection of the Knee in Indian Scenario: A Retrospective Analysis of Outcomes
Praharsha Mulpur, Sukesh Rao Sankineani, Chiranjeevi Thayi, A. V. Gurava Reddy
Indian Journal of Orthopaedics. 2021; 55(4): 961
[Pubmed] | [DOI]
56 Hydrazonoyl bromide precursors as DHFR inhibitors for the synthesis of bis-thiazolyl pyrazole derivatives; antimicrobial activities, antibiofilm, and drug combination studies against MRSA
Seham A. Ibrahim, Eman A. Fayed, Hala F. Rizk, Said E. Desouky, Ahmed Ragab
Bioorganic Chemistry. 2021; 116: 105339
[Pubmed] | [DOI]
57 Antimicrobial resistance: A challenge awaiting the post-COVID-19 era
Tekle Airgecho Lobie, Aklilu Abrham Roba, James Alexander Booth, Knut Ivan Kristiansen, Abraham Aseffa, Kirsten Skarstad, Magnar Bjørås
International Journal of Infectious Diseases. 2021; 111: 322
[Pubmed] | [DOI]
58 Hidden suppressive interactions are common in higher-order drug combinations
Natalie Ann Lozano-Huntelman, April Zhou, Elif Tekin, Mauricio Cruz-Loya, Bjørn Østman, Sada Boyd, Van M. Savage, Pamela Yeh
iScience. 2021; 24(4): 102355
[Pubmed] | [DOI]
59 Influence of bacterial culture medium on peptidoglycan binding of cell wall lytic enzymes
Amala Bhagwat, Fuming Zhang, Cynthia H. Collins, Jonathan S. Dordick
Journal of Biotechnology. 2021; 330: 27
[Pubmed] | [DOI]
60 Prevalence of multidrug-resistant bacteria in Ethiopia: a systematic review and meta-analysis
Tsegaye Alemayehu
Journal of Global Antimicrobial Resistance. 2021; 26: 133
[Pubmed] | [DOI]
61 Environmental antimicrobial resistance and its drivers: a potential threat to public health
Samreen, Iqbal Ahmad, Hesham A. Malak, Hussein H. Abulreesh
Journal of Global Antimicrobial Resistance. 2021; 27: 101
[Pubmed] | [DOI]
62 Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?
Soumya Ghosh, Charné Bornman, Mai M. Zafer
Journal of Infection and Public Health. 2021; 14(5): 555
[Pubmed] | [DOI]
63 Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Tanvir Mahtab Uddin, Arka Jyoti Chakraborty, Ameer Khusro, BM Redwan Matin Zidan, Saikat Mitra, Talha Bin Emran, Kuldeep Dhama, Md. Kamal Hossain Ripon, Márió Gajdács, Muhammad Umar Khayam Sahibzada, Md. Jamal Hossain, Niranjan Koirala
Journal of Infection and Public Health. 2021;
[Pubmed] | [DOI]
64 Rational use of antimicrobials in the treatment of upper airway infections
Santiago Alfayate Miguélez, Luis Garcia-Marcos
Jornal de Pediatria (Versão em Português). 2020; 96: 111
[Pubmed] | [DOI]
65 Simple visualized readout of suppressed coffee ring patterns for rapid and isothermal genetic testing of antibacterial resistance
Yoo Kyung Kang, San Hae Im, Jea Sung Ryu, Jaehyun Lee, Hyun Jung Chung
Biosensors and Bioelectronics. 2020; 168: 112566
[Pubmed] | [DOI]
66 Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair
Claudia C Orelio, Coen van Hessen, Francisco Javier Sanchez-Manuel, Theodorus J Aufenacker, Rob JPM Scholten
Cochrane Database of Systematic Reviews. 2020;
[Pubmed] | [DOI]
67 Evolving Technologies and Strategies for Combating Antibacterial Resistance in the Advent of the Postantibiotic Era
Didem Sen Karaman, Utku Kürsat Ercan, Emel Bakay, Nermin Topaloglu, Jessica M. Rosenholm
Advanced Functional Materials. 2020; 30(15): 1908783
[Pubmed] | [DOI]
68 Reprogramming of antibiotics to combat antimicrobial resistance
Kashyap K. Dubey, Indu, Manisha Sharma
Archiv der Pharmazie. 2020; 353(11): 2000168
[Pubmed] | [DOI]
69 Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety
Maryam Norouzbahari, Somayeh Salarinejad, Mümtaz Güran, Gizem Sanlitürk, Zahra Emamgholipour, Hamid Reza Bijanzadeh, Mahsa Toolabi, Alireza Foroumadi
DARU Journal of Pharmaceutical Sciences. 2020; 28(2): 661
[Pubmed] | [DOI]
70 Increasing Globalization and the Movement of Antimicrobial Resistance between Countries
Allison E. Berndtson
Surgical Infections. 2020; 21(7): 579
[Pubmed] | [DOI]
71 Treatment strategies targeting persister cell formation in bacterial pathogens
Fazlurrahman Khan, Dung Thuy Nguyen Pham, Nazia Tabassum, Sandra Folarin Oloketuyi, Young-Mog Kim
Critical Reviews in Microbiology. 2020; 46(6): 665
[Pubmed] | [DOI]
72 Antibiotic use in Kenyan public hospitals: Prevalence, appropriateness and link to guideline availability
Michuki Maina, Paul Mwaniki, Edwin Odira, Nduku Kiko, Jacob McKnight, Constance Schultsz, Mike English, Olga Tosas-Auguet
International Journal of Infectious Diseases. 2020; 99: 10
[Pubmed] | [DOI]
73 Occurrence and toxicity of antibiotics in the aquatic environment: A review
Pavla Kovalakova, Leslie Cizmas, Thomas J. McDonald, Blahoslav Marsalek, Mingbao Feng, Virender K. Sharma
Chemosphere. 2020; 251: 126351
[Pubmed] | [DOI]
74 Antisense antibacterial compounds
Reed Pifer, David E. Greenberg
Translational Research. 2020; 223: 89
[Pubmed] | [DOI]
75 Synthesis and Biological Evaluation of New Pyridothienopyrimidine Derivatives as Antibacterial Agents and Escherichia coli Topoisomerase II Inhibitors
Eman M. Mohi El-Deen, Eman A. Abd El-Meguid, Eman A. Karam, Eman S. Nossier, Marwa F. Ahmed
Antibiotics. 2020; 9(10): 695
[Pubmed] | [DOI]
76 Knowledge, Attitudes and Perceptions of Medical Students on Antimicrobial Stewardship
Panagiotis Efthymiou, Despoina Gkentzi, Gabriel Dimitriou
Antibiotics. 2020; 9(11): 821
[Pubmed] | [DOI]
77 Silver Antibacterial Synergism Activities with Eight Other Metal(loid)-Based Antimicrobials against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus
Ali Pormohammad, Raymond J. Turner
Antibiotics. 2020; 9(12): 853
[Pubmed] | [DOI]
78 Facile Synthesis of Antimicrobial Aloe Vera-“Smart” Triiodide-PVP Biomaterials
Zehra Edis, Samir Haj Bloukh
Biomimetics. 2020; 5(3): 45
[Pubmed] | [DOI]
79 Antimicrobial Stewardship Programs in Resource Constrained Environments: Understanding and Addressing the Need of the Systems
Ashish Kumar Kakkar, Nusrat Shafiq, Gurpreet Singh, Pallab Ray, Vikas Gautam, Ritesh Agarwal, Jayashree Muralidharan, Pankaj Arora
Frontiers in Public Health. 2020; 8
[Pubmed] | [DOI]
80 Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter
Sameer Dhingra, Nor Azlina A. Rahman, Ed Peile, Motiur Rahman, Massimo Sartelli, Mohamed Azmi Hassali, Tariqul Islam, Salequl Islam, Mainul Haque
Frontiers in Public Health. 2020; 8
[Pubmed] | [DOI]
81 Antimicrobial Use in Extensive Smallholder Livestock Farming Systems in Ethiopia: Knowledge, Attitudes, and Practices of Livestock Keepers
Biruk Alemu Gemeda, Kebede Amenu, Ulf Magnusson, Ian Dohoo, Gunilla Ström Hallenberg, Gezahegn Alemayehu, Hiwot Desta, Barbara Wieland
Frontiers in Veterinary Science. 2020; 7
[Pubmed] | [DOI]
82 Antibiotic Resistance: Moving From Individual Health Norms to Social Norms in One Health and Global Health
Sara Hernando-Amado, Teresa M. Coque, Fernando Baquero, José L. Martínez
Frontiers in Microbiology. 2020; 11
[Pubmed] | [DOI]
83 Socioeconomic factors associated with antimicrobial resistance of Pseudomonas aeruginosa, Staphylococcus aureus, and Escherichia coli in Chilean hospitals (2008–2017)
Kasim Allel, Patricia García, Jaime Labarca, José M. Munita, Magdalena Rendic, Grupo Colaborativo de Resistencia Bacteriana, Eduardo A. Undurraga
Revista Panamericana de Salud Pública. 2020; 44: 1
[Pubmed] | [DOI]
84

Prevalence and Factors Associated with Parents Self-Medicating Under-Fives with Antibiotics in Bagamoyo District Council, Tanzania: a Cross-Sectional Study

Beatus Simon, Method Kazaura
Patient Preference and Adherence. 2020; Volume 14: 1445
[Pubmed] | [DOI]
85 Personalized antibiotic therapy – a rapid high performance liquid chromatography–tandem mass spectrometry method for the quantitation of eight antibiotics and voriconazole for patients in the intensive care unit
Tony Böhle, Ulrike Georgi, Dewi Fôn Hughes, Oliver Hauser, Gudrun Stamminger, Dirk Pohlers
Journal of Laboratory Medicine. 2020; 44(6): 335
[Pubmed] | [DOI]
86 Inhalation antibacterial drugs: current opportunities for use in respiratory infections
S. K. Zyryanov, O. I. Butranova
Russian Pulmonology. 2020; 30(3): 320
[Pubmed] | [DOI]
87 Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial
Olawale Salami, Philip Horgan, Catrin E. Moore, Abhishek Giri, Asadu Sserwanga, Ashish Pathak, Buddha Basnyat, Francois Kiemde, Frank Smithuis, Freddy Kitutu, Gajanan Phutke, Halidou Tinto, Heidi Hopkins, James Kapisi, Myo Maung Maung Swe, Neelam Taneja, Rita Baiden, Shanta Dutta, Adelaide Compaore, David Kaawa-Mafigiri, Rashida Hussein, Summita Udas Shakya, Vida Kukula, Stefano Ongarello, Anjana Tomar, Sarabjit S. Chadha, Kamini Walia, Cassandra Kelly-Cirino, Piero Olliaro
Trials. 2020; 21(1)
[Pubmed] | [DOI]
88 Pharmacovigilance and incidence of adverse drug reactions in hospitalized pediatric patients: a mini systematic review
Zakir Khan, Khayal Muhammad, Yusuf Karatas, Cagri Bilen, Farman Ullah Khan, Faiz Ullah Khan
Egyptian Pediatric Association Gazette. 2020; 68(1)
[Pubmed] | [DOI]
89 Acquisition and Long-term Carriage of Multidrug-Resistant Organisms in US International Travelers
Colin J Worby, Ashlee M Earl, Sarah E Turbett, Margaret Becker, Sowmya R Rao, Elizabeth Oliver, Allison Taylor Walker, Maroya Walters, Paul Kelly, Daniel T Leung, Mark Knouse, Stefan H F Hagmann, Edward T Ryan, Regina C LaRocque
Open Forum Infectious Diseases. 2020; 7(12)
[Pubmed] | [DOI]
90 A Cross-sectional Study of Group B Streptococcus–Associated Sepsis, Coinfections, and Antibiotic Susceptibility Profile in Neonates in Pakistan
Samra Asghar, Junaid Ali Khan, Muhammad Shahid Mahmood, Muhammad Imran Arshad
Advances in Neonatal Care. 2020; 20(4): E59
[Pubmed] | [DOI]
91 Antibacterial activity of Xenorhabdus and Photorhabdus isolated from entomopathogenic nematodes against antibiotic-resistant bacteria
Paramaporn Muangpat, Manawat Suwannaroj, Thatcha Yimthin, Chamaiporn Fukruksa, Sutthirat Sitthisak, Narisara Chantratita, Apichat Vitta, Aunchalee Thanwisai, Filippo Giarratana
PLOS ONE. 2020; 15(6): e0234129
[Pubmed] | [DOI]
92 Clinical signs predictive of influenza virus infection in Cameroon
Chavely Gwladys Monamele, Cyprien Kengne-Nde, Hermann Landry Munshili Njifon, Mohamadou Ripa Njankouo, Sebastien Kenmoe, Richard Njouom, Binod Kumar
PLOS ONE. 2020; 15(7): e0236267
[Pubmed] | [DOI]
93 Factors Associated with Multidrug-Resistant Pathogens in Community-Acquired Pneumonia Patients Hospitalized in a Provincial Teaching Hospital in Indonesia
Arto Yuwono Soeroto, Ining Kartika Tarmidi, Guntur Darmawan, Geraldo Laurus, Prayudi Santoso
Shiraz E-Medical Journal. 2020; 22(1)
[Pubmed] | [DOI]
94 Frequency of Extensively Drug-Resistant Gram-Negative Pathogens in a Tertiary Care Hospital in Pakistan
Sundas Abbas, Asad Ullah Sabir, Noor Khalid, Sarah Sabir, Sana Khalid, Shawal Haseeb, Muhammad Numair Khan, Waqas M Ajmal, Faryal Azhar, M.Talha Saeed
Cureus. 2020;
[Pubmed] | [DOI]
95 Changing Susceptibility Pattern of Vibrio cholerae O1 Isolates to Commonly Used Antibiotics in the Largest Diarrheal Disease Hospital in Bangladesh during 2000–2018
Irin Parvin, K. M. Shahunja, Soroar Hossain Khan, Tahmina Alam, Lubaba Shahrin, Mst. Mahmuda Ackhter, Monira Sarmin, Sampa Dash, Muhammad Waliur Rahman, Abu Sadat Mohammad Sayeem Bin Shahid, Abu Syed Golam Faruque, Tahmeed Ahmed, Mohammod Jobayer Chisti
The American Journal of Tropical Medicine and Hygiene. 2020; 103(2): 652
[Pubmed] | [DOI]
96 A Probiotic-Based Sanitation System for the Reduction of Healthcare Associated Infections and Antimicrobial Resistances: A Budget Impact Analysis
Rosanna Tarricone, Carla Rognoni, Luca Arnoldo, Sante Mazzacane, Elisabetta Caselli
Pathogens. 2020; 9(6): 502
[Pubmed] | [DOI]
97 “Smart” Antimicrobial Nanocomplexes with Potential to Decrease Surgical Site Infections (SSI)
Zehra Edis, Samir Haj Bloukh, May Reda Ibrahim, Hamed Abu Sara
Pharmaceutics. 2020; 12(4): 361
[Pubmed] | [DOI]
98 Evaluation of Medication Use Pattern Among Patients Presenting to the Emergency Department of Hiwot Fana Specialized University Hospital, Using WHO Prescribing Indicators
Kirubel Minsamo Mishore, Yabsira Girma, Assefa Tola, Abraham Nigussie Mekuria, Yohanes Ayele
Frontiers in Pharmacology. 2020; 11
[Pubmed] | [DOI]
99 Preliminary Assessment of the Mucosal Toxicity of Tea Tree (Melaleuca alternifolia) and Rosemary (Rosmarinus officinalis) Essential Oils on Novel Porcine Uterus Models
Martina Bertocchi, Antonella Rigillo, Alberto Elmi, Domenico Ventrella, Camilla Aniballi, Diana G. Scorpio, Maurizio Scozzoli, Giuliano Bettini, Monica Forni, Maria Laura Bacci
International Journal of Molecular Sciences. 2020; 21(9): 3350
[Pubmed] | [DOI]
100 Isolation, Genomic and Metabolomic Characterization of Streptomyces tendae VITAKN with Quorum Sensing Inhibitory Activity from Southern India
Nabila Mohammed Ishaque, Ilia Burgsdorf, Jessie James Limlingan Malit, Subhasish Saha, Roberta Teta, Daniela Ewe, Krishnan Kannabiran, Pavel Hrouzek, Laura Steindler, Valeria Costantino, Kumar Saurav
Microorganisms. 2020; 8(1): 121
[Pubmed] | [DOI]
101 Antibacterial Activity of Four Plant Extracts Extracted from Traditional Chinese Medicinal Plants against Listeria monocytogenes, Escherichia coli, and Salmonella enterica subsp. enterica serovar Enteritidis
R.L. McMurray, M.E.E. Ball, M.M. Tunney, N. Corcionivoschi, C. Situ
Microorganisms. 2020; 8(6): 962
[Pubmed] | [DOI]
102 Synthesis, Characterization, and Biological Evaluation of Novel 7-Oxo-7H-thiazolo[3,2-b]-1,2,4-triazine-2-carboxylic Acid Derivatives
Dong Cai, Tai Li, Qian Xie, Xiaofei Yu, Wei Xu, Yu Chen, Zhe Jin, Chun Hu
Molecules. 2020; 25(6): 1307
[Pubmed] | [DOI]
103 DESCRIÇÃO DE RÓTULOS DE MEDICAMENTOS COMO ESTRATÉGIA PARA IDENTIFICAÇÃO DE MEDICAMENTOS FALSIFICADOS
Augusto Santana Palma Silva, Sheila Torres Feitosa Silva
Infarma - Ciências Farmacêuticas. 2019; 31(3): 205
[Pubmed] | [DOI]
104 Grape Pomace as a Promising Antimicrobial Alternative in Feed: A Critical Review
Yousef I. Hassan, Veronika Kosir, Xianhua Yin, Kelly Ross, Moussa S. Diarra
Journal of Agricultural and Food Chemistry. 2019; 67(35): 9705
[Pubmed] | [DOI]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Methods
   Results
   Conclusion
   Summary
    References
    Article Figures

 Article Access Statistics
    Viewed15130    
    Printed256    
    Emailed0    
    PDF Downloaded1066    
    Comments [Add]    
    Cited by others 104    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008